Table 4.
Radiofrequency Ablation Effect on Biomarkers
| Biomarkers N=190 | Baseline | 95% CI | Post‐RFA | 95% CI | Day After RFA | 95% CI | P Value |
|---|---|---|---|---|---|---|---|
| NT‐proBNP, pg/mL | 187.1 | 156.6 to 223.4 | 189.8 | 161.4 to 223.2 | 243.5 | 217.9 to 272.1 | 0.886 |
| MR‐proANP, pmol/L | 132.5 | 122.7 to 143.1 | 196.7 | 182.9 to 211.6 | 100.5 | 93.2 to 108.5 | <0.001 |
| Copeptin, pmol/L | 8.6 | 7.57 to 9.88 | 53.5 | 44.7 to 64.1 | 8.19 | 7.42 to 9.05 | <0.001 |
| MR‐proADM, nmol/L | 0.682 | 0.655 to 0.708 | 0.6211 | 0.598 to 0.644 | 0.811 | 0.778 to 0.844 | <0.001 |
Data are presented as geometric means with 95% CI, but MR‐proADM is presented as mean with 95% CI. Analyses of the course of peptides were performed with repeated‐measurements ANOVA and were adjusted for covariates: BMI >30, GFR <60 mL/min per 1.73 m2, EF <50%, age >65 years, heart rate >100/min, E/E′, and sex. The potential statistical significance of those analyses are presented with P values. BMI indicates body mass index; EF, ejection fraction; GFR, glomerular filtration rate; MR‐proADM, midregional portion of proadrenomedullin; MR‐proANP, midregional fragment of the N‐terminal precursor of atrial natriuretic peptide; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.